COVID-19: Vaccines and Therapeutics
The Food and Drug Administration authorized administering a single booster dose of the Moderna and Johnson & Johnson COVID-19 vaccines to eligible individuals, and authorized eligible recipients of all three authorized COVID-19 vaccines to receive a different COVID-19 vaccine for their initial…
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted unanimously to recommend a single COVID-19 vaccine booster dose at least six months after completing an initial mRNA COVID-19 vaccine series, in the same risk groups for whom CDC recommended a Pfizer…
A mix-and-match vaccine regimen is permissible for international travelers entering the U.S., according to updated Centers for Disease Control and Prevention guidance.
Treatment with subcutaneous interferon beta-1a plus remdesivir was not superior to treatment with remdesivir alone in a clinical trial that enrolled 969 hospitalized adults with COVID-19 pneumonia in the United States, Japan, Mexico, Singapore and South Korea, the National Institutes of Health…
Two doses of the Pfizer vaccine are 93% effective at preventing COVID-19 hospitalization among children aged 12 to 18, according to a study at 19 pediatric hospitals released by the Centers for Disease Control and Prevention.
As of early October 2021, the health system reached a 99% vaccination rate among staff and more than 600,000 people were vaccinated throughout the region.
The Centers for Disease Control and Prevention released an operational planning guide for pediatric COVID-19 vaccination and preliminary information on the pediatric Pfizer COVID-19 vaccine.
Available data support the safety and effectiveness of the Johnson & Johnson COVID-19 vaccine for emergency use authorization as a booster dose in individuals aged 18 and older at least two months after an initial single dose, the Food and Drug Administration’s Vaccines and Related Biological…
New COVID-19 vaccine strategies to reach people still not vaccinated are under development.
A Food and Drug Administration advisory panel voted unanimously to recommend an extra Moderna booster dose for certain individuals.